IQWiG reports added benefit not proven for lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma

On 16 March 2026, IQWiG completed project A25-153 for lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma and reported added benefit not proven, citing absence of direct comparator-aligned evidence and methodological limitations of unanchored MAIC analyses built from single-arm sources.